NA
NVO

NewEdge Advisors’s Novo Nordisk NVO Stock Holding History

NewEdge Advisors’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.59M Sell
74,834
-5,402
-7% -$232K 0.01% 916
2026
Q1 		$2.95M Sell
80,236
-5,775
-7% -$274K 0.01% 912
2025
Q4 		$4.38M Buy
86,011
+2,234
+3% +$114K 0.02% 714
2025
Q3 		$4.65M Sell
83,777
-26,177
-24% -$1.53M 0.02% 658
2025
Q2 		$7.59M Sell
109,954
-322,391
-75% -$21.9M 0.04% 439
2025
Q1 		$30M Buy
432,345
+97,377
+29% +$8.04M 0.18% 115
2024
Q4 		$28.8M Buy
334,968
+12,813
+4% +$1.39M 0.17% 122
2024
Q3 		$38.4M Buy
322,155
+3,575
+1% +$477K 0.25% 90
2024
Q2 		$45.5M Buy
318,580
+228,889
+255% +$30.3M 0.33% 57
2024
Q1 		$11.5M Buy
89,691
+17,390
+24% +$2.07M 0.1% 204
2023
Q4 		$7.53M Buy
72,301
+21,003
+41% +$2.08M 0.07% 265
2023
Q3 		$4.66M Buy
51,298
+8,092
+19% +$713K 0.05% 335
2023
Q2 		$3.5M Buy
43,206
+19,100
+79% +$1.56M 0.04% 409
2023
Q1 		$1.93M Sell
24,106
-3,264
-12% -$231K 0.02% 553
2022
Q4 		$1.17M Buy
27,370
+3,204
+13% +$188K 0.03% 470
2022
Q3 		$1.2M Sell
24,166
-1,558
-6% -$83.5K 0.02% 576
2022
Q2 		$1.43M Sell
25,724
-19,320
-43% -$1.07M 0.02% 531
2022
Q1 		$2.5M Sell
45,044
-1,350
-3% -$69.3K 0.04% 375
2021
Q4 		$2.6M Buy
46,394
+20,154
+77% +$1.09M 0.04% 377
2021
Q3 		$1.26M Sell
26,240
-2,364
-8% -$114K 0.03% 445
2021
Q2 		$1.2M Buy
28,604
+2,802
+11% +$109K 0.03% 441
2021
Q1 		$870K Buy
25,802
+19,292
+296% +$687K 0.03% 495
2020
Q4 		$227K Hold
6,510
– – 0.01% 854
2020
Q3 		$226K Sell
6,510
-216
-3% -$7.2K 0.01% 789
2020
Q2 		$220K Buy
+6,726
New +$215K 0.01% 753
2017
Q3 		– Sell
-162
Closed -$3.41K – 863
2017
Q2 		$3.41K Buy
+162
New +$3.27K ﹤0.01% 1221

Other funds holding NVO

Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

NewEdge Advisors's NVO Position: Q2 2026 in Review

NewEdge Advisors reduced its Novo Nordisk (NVO) stake by 6.7% in Q2 2026, selling an estimated $232K and leaving 74,834 shares worth $3.59M. The position accounts for 0.01% of the portfolio, ranked #916.

NewEdge Advisors first reported a position in NVO in Q2 2017 and has held it in 26 quarters since. The position peaked at $45.5M in Q2 2024. 1,350 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • NewEdge Advisors held 74,834 shares of Novo Nordisk worth $3.59M as of Q2 2026.
  • NewEdge Advisors sold 5,402 Novo Nordisk shares in Q2 2026, an estimated $232K.
  • Novo Nordisk made up 0.01% of NewEdge Advisors's portfolio in Q2 2026, its #916 holding.
  • NewEdge Advisors first reported a position in Novo Nordisk in Q2 2017 and has held it in 26 quarters since.
  • NewEdge Advisors's Novo Nordisk position peaked at $45.5M in Q2 2024.
  • 1,350 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on NewEdge Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.